Skip to Content

Isavuconazonium Dosage

Applies to the following strength(s): 186 mg ; 372 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Aspergillosis - Invasive

Loading Dose: 372 mg IV or orally every 8 hours for 6 doses (48 hours)
Maintenance Dose: 372 mg IV or orally once a day

Comments:
-Isavuconazonium sulfate is the prodrug of isavuconazole; 372 mg of isavuconazonium sulfate is equivalent to 200 mg of isavuconazole.
-Maintenance doses should be started 12 to 24 hours after the last loading dose.

Usual Adult Dose for Mucormycosis - Invasive

Loading Dose: 372 mg IV or orally every 8 hours for 6 doses (48 hours)
Maintenance Dose: 372 mg IV or orally once a day

Comments:
-Isavuconazonium sulfate is the prodrug of isavuconazole; 372 mg of isavuconazonium sulfate is equivalent to 200 mg of isavuconazole.
-Maintenance doses should be started 12 to 24 hours after the last loading dose.

Renal Dose Adjustments

Mild, moderate, or severe renal dysfunction: No adjustment recommended.

Liver Dose Adjustments

Mild to moderate liver dysfunction (Child-Pugh A and B): No adjustment recommended.
Severe liver dysfunction (Child-Pugh C): Data not available

Comments: This drug should be used in patients with severe liver dysfunction only if the benefits outweigh the risks.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

ESRD: No adjustment recommended.

Other Comments

Administration advice:
-Administer IV formulation via an infusion set with an in-line filter (pore size 0.2 to 1.2 micron).
-Infuse the IV formulation over a minimum of 1 hour in 250 mL of compatible diluent (to reduce risk for infusion-related reactions); do not administer as IV bolus injection.
-Do not infuse with any other IV drugs.
-Flush IV lines with 0.9% sodium chloride injection, USP or 5% dextrose injection, USP before and after infusion.
-Avoid unnecessary vibration or vigorous shaking of the diluted IV solution; do not use a pneumatic transport system.
-May switch between IV and oral formulations (bioequivalent); no loading dose needed when switching between formulations.
-Swallow capsules whole; do not chew, crush, dissolve, or open capsules.
-May administer capsules without regard to food.

Storage requirements:
-Capsules: Store at 20C to 25C (68F to 77F) in the original bottle to protect from moisture; excursion permitted to 15C to 30C (59F to 86F).
-IV (unreconstituted vials): Store at 2C to 8C (36F to 46F) in refrigerator.
-IV (reconstituted solution): Should use immediately; may be stored below 25C up to 1 hour before preparation of the patient infusion solution
-IV (diluted infusion solution): Complete infusion within 6 hours of dilution at room temperature (20C to 25C [68F to 77F]); if this is not possible, refrigerate (2C to 8C [36F to 46F]) the infusion solution immediately after dilution and complete infusion within 24 hours; do not freeze.

Reconstitution/preparation techniques:
-IV formulation requires reconstitution and then dilution before infusion; the manufacturer product information should be consulted.

IV compatibility:
-Compatible diluents: 0.9% sodium chloride injection, USP; 5% dextrose injection, USP

General:
-Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained before therapy to isolate and identify causative organisms; therapy may be started before results are known, but once available, antifungal therapy should be adjusted accordingly.

Monitoring:
-General: For drug-related side effects in patients with severe liver dysfunction
-Hepatic: Liver-related laboratory tests (at the start of and during therapy); for more severe hepatic injury in patients with abnormal liver-related laboratory tests (during therapy)

Hide